Optogenetics, a cutting-edge tool in novel gene manipulation and drug discovery, holds significant therapeutic potential for a variety of neurological disorders, including retinal diseases. Retinal diseases such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP), significantly impair quality of life and cause severe visual impairment due to limited treatment options and a general lack of awareness. The increasing incidence of these degenerative conditions underscores the need for innovative solutions, such as optogenetics. Optogenetic therapy introduces genes coding for light-sensitive proteins, which are controlled by light signals to make neurons photosensitive. This precise targeting approach does not require specific gene intervention and can bypass dysfunctional photoreceptors, offering a treatment option for various degenerative and dystrophic eye diseases. Successful outcomes in patients with late-stage genetic retinal diseases and numerous clinical trials suggest that optogenetics could be an effective treatment for humans. This review provides an overview of the current landscape of optogenetic therapy, discusses its challenges, and summarizes the findings of ongoing clinical trials for neural and visual restoration.
MalekGBusikJGrantMB, et al.Models of retinal diseases and their applicability in drug discovery. Expert Opin Drug Discov2018; 13: 359–377.
2.
TemponeMHBorges-MartinsVPCésarF, et al.The healthy and diseased retina seen through neuron–Glia interactions. Int J Mol Sci2024; 25: 1120.
3.
LozanoBLLCervantesALA. Development of experimental treatments for patients with retinitis pigmentosa. Archivos de la Sociedad Española de Oftalmología (English Edition)2023; 98: 646–655.
4.
TsangSHSharmaT. Leber congenital amaurosis. Adv Exp Med Biol2018; 1085: 131–137.
5.
HuangCHYangCMYangCH, et al.Leber’s congenital amaurosis: current concepts of genotype-phenotype correlations. Genes (Basel)2021; 12: 11–12.
BoydenES. A history of optogenetics: the development of tools for controlling brain circuits with light. F1000 Biol Rep2011; 3: 5–8.
18.
JoshiJRubartMZhuW. Optogenetics: background, methodological advances and potential applications for cardiovascular research and medicine. Front Bioeng Biotechnol2020; 7: 1–2.
19.
KimCKAdhikariADeisserothK. Integration of optogenetics with complementary methodologies in systems neuroscience. Nat Rev Neurosci2017; 18: 222–235.
20.
HäusserM. Optogenetics: the age of light. Nat Methods2014; 11: 1012–1014.
21.
LanT-HHeLHuangY, et al.Optogenetics for transcriptional programming and genetic engineering. Trends Genet2022; 38: 1253–1270.
22.
LindnerMGilhooleyMJPeirsonSN, et al.The functional characteristics of optogenetic gene therapy for vision restoration. Cell Mol Life Sci2021; 78: 1597–1613.
23.
KlapperSDSwiersyABambergE, et al.Biophysical properties of optogenetic tools and their application for vision restoration approaches. Front Syst Neurosci2016; 10: 1–11.
24.
StryerL. Cyclic GMP cascade of vision. Annu Rev Neurosci1986; 9: 87–119.
25.
BaylorDALambTDYauKW. Responses of retinal rods to single photons. J Physiol1979; 288: 613–634.
26.
KuriharaMSudoY. Microbial rhodopsins: wide distribution, rich diversity and great potential. Biophys Physicobiol2015; 12: 121–129.
27.
NutschTMarwanWOesterheltD, et al.Signal processing and flagellar motor switching during phototaxis of Halobacterium salinarum. Genome Res2003; 13: 2406–2412.
28.
DeisserothK. Optogenetics: 10 years of microbial opsins in neuroscience. Nat Neurosci2015; 18: 1213–1225.
29.
ZhangFVierockJYizharO, et al.The microbial opsin family of optogenetic tools. Cell2011; 147: 1446–1457.
30.
NagelGSzellasTHuhnW, et al.Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. Proc Natl Acad Sci U S A2003; 100: 13940–13945.
31.
LinJYLinMZSteinbachP, et al.Characterization of engineered channelrhodopsin variants with improved properties and kinetics. Biophys J2009; 96: 1803–1814.
32.
LinJY. A user’s guide to channelrhodopsin variants: features, limitations and future developments. Exp Physiol2011; 96: 19–25.
33.
LagaliPSBalyaDAwatramaniGB, et al.Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nat Neurosci2008; 11: 667–675.
34.
PanZ-HGanjawalaTHLuQ, et al.Chr2 mutants at L132 and T159 with improved operational light sensitivity for vision restoration. PLoS One2014; 9: e98924.
35.
SahelJABoulanger-ScemamaEPagotC, et al.Partial recovery of visual function in a blind patient after optogenetic therapy. Nat Med2021; 27: 1223–1229.
36.
CheongSKStrazzeriJMWilliamsDR, et al.All-optical recording and stimulation of retinal neurons in vivo in retinal degeneration mice. PLoS One2018; 13: e0194947.
37.
KlapoetkeNCMurataYKimSS, et al.Addendum: independent optical excitation of distinct neural populations. Nat Methods2014; 11: 972.
38.
McGregorJEKunalaKXuZ, et al.Optogenetic therapy restores retinal activity in primate for at least a year following photoreceptor ablation. Mol Ther2022; 30: 1315–1328.
39.
FeldbauerKZimmermannDPintschoviusV, et al.Channelrhodopsin-2 is a leaky proton pump. Proc Natl Acad Sci U S A2009; 106: 12317–12322.
40.
ChuongASMiriMLBusskampV, et al.Noninvasive optical inhibition with a red-shifted microbial rhodopsin. Nat Neurosci2014; 17: 1123–1129.
41.
LindnerMGilhooleyMJHughesS, et al.Optogenetics for visual restoration: from proof of principle to translational challenges. Prog Retin Eye Res2022; 91: 2–16.
42.
De SilvaSRBarnardARHughesS, et al.Long-term restoration of visual function in end-stage retinal degeneration using subretinal human melanopsin gene therapy. Proc Natl Acad Sci USA2017; 114: 11211–11216.
43.
BallisterERRodgersJMartialF, et al.A live cell assay of GPCR coupling allows identification of optogenetic tools for controlling Go and Gi signaling. BMC Biol2018; 16: 10.
44.
SpoidaKEickelbeckDKarapinarR, et al.Melanopsin variants as intrinsic optogenetic on and off switches for transient versus sustained activation of G protein pathways. Curr Biol2016; 26: 1206–1212.
45.
HattarSLucasRJMrosovskyN, et al.Melanopsin and rod–cone photoreceptive systems account for all major accessory visual functions in mice. Nature2003; 424: 75–81.
46.
KoyanagiMKubokawaKTsukamotoH, et al.Cephalochordate melanopsin: evolutionary linkage between invertebrate visual cells and vertebrate photosensitive retinal ganglion cells. Curr Biol2005; 15: 1065–1069.
47.
DoMTH. Melanopsin and the intrinsically photosensitive retinal ganglion cells: biophysics to behavior. Neuron2019; 104: 205–226.
48.
GilhooleyMJLindnerMPalumaaT, et al.A systematic comparison of optogenetic approaches to visual restoration. Mol Ther Methods Clin Dev2022; 25: 111–123.
49.
HickeyDHughesSDaviesWL, et al.Human opsin-G-protein fusion proteins as potential light sensitizers. Invest Ophthalmol Vis Sci2014; 55: 5768–5768.
50.
Cehajic-KapetanovicJEleftheriouCAllenAE, et al.Restoration of vision with ectopic expression of human rod opsin. Curr Biol2015; 25: 2111–2122.
51.
BerryMHHoltASalariA, et al.Restoration of high-sensitivity and adapting vision with a cone opsin. Nat Commun2019; 10: 1221.
52.
McClementsMEStaurenghiFViselM, et al.AAV Induced expression of human rod and cone opsin in bipolar cells of a mouse model of retinal degeneration. Biomed Res Int2021; 2021: 1–8.
53.
McGregorJEGodatTDhakalKR, et al.Optogenetic restoration of retinal ganglion cell activity in the living primate. Nat Commun2020; 11: 1703.
54.
SeitzIPMichalakisSWilhelmB, et al.Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman primates. Investigative Opthalmology & Visual Science2017; 58: 5792.
55.
van WykMPielecka-FortunaJLöwelS, et al.Restoring the ON switch in blind retinas: opto-mGluR6, a next-generation, cell-tailored optogenetic tool. PLoS Biol2015; 13: e1002143.
56.
KralikJKleinlogelS. Functional availability of ON-bipolar cells in the degenerated retina: timing and longevity of an optogenetic gene therapy. Int J Mol Sci2021; 22: 11515.
57.
KatadaYYoshidaKSerizawaN, et al.High-sensitivity vision restoration via ectopic expression of chimeric rhodopsin in mice. bioRxiv2022; 26: 2020.09.17.301523.
58.
BatabyalSGajjeramanSPradhanS, et al.Sensitization of ON-bipolar cells with ambient light activatable multi-characteristic opsin rescues vision in mice. Gene Ther2021; 28: 162–176.
59.
TchedreKTBatabyalSGaliciaM, et al.Biodistribution of adeno-associated virus type 2 carrying multi-characteristic opsin in dogs following intravitreal injection. J Cell Mol Med2021; 25: 8676–8686.
60.
EickelbeckDRudackTTennigkeitSA, et al.Lamprey parapinopsin (“UVLamP”): a bistable UV-sensitive optogenetic switch for ultrafast control of GPCR pathways. ChemBioChem2020; 21: 612–617.
61.
NuzbrokhYKassotisASRagiSD, et al.Treatment-Emergent adverse events in gene therapy trials for inherited retinal diseases: a narrative review. Ophthalmol Ther2020; 9: 709–724.
62.
DalkaraDByrneLCKlimczakRR, et al.In vivo–directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med2013; 5: 8.
63.
HulligerECHostettlerSMKleinlogelS. Empowering retinal gene therapy with a specific promoter for human rod and cone ON-bipolar cells. Mol Ther Methods Clin Dev2020; 17: 505–519.
64.
GilhooleyMJOwenNMoosajeeM, et al.From transcriptomics to treatment in inherited optic neuropathies. Genes (Basel)2021; 12: 147.
65.
WangYRajalaACaoB, et al.Cell-Specific promoters enable lipid-based nanoparticles to deliver genes to specific cells of the retina In Vivo. Theranostics2016; 6: 1514–1527.
66.
SpSMitraRNZhengM, et al.Gene augmentation for autosomal dominant retinitis pigmentosa using rhodopsin genomic loci nanoparticles in the P23H+/− knock-in murine model. Gene Ther2023; 30: 628–640.
ZhaoZAnselmoACMitragotriS. Viral vector-based gene therapies in the clinic. Bioeng Transl Med2022; 7: 2–3.
69.
TabebordbarMLagerborgKAStantonA, et al.Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell2021; 184: 4919–4938.e22.
70.
NasoMFTomkowiczBPerryWL, et al.Adeno-Associated virus (AAV) as a vector for gene therapy. BioDrugs2017; 31: 317–334.
71.
ErtlHCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol2022; 13: 6.
72.
AuHKEIsalanMMielcarekM. Gene therapy advances: a meta-analysis of AAV usage in clinical settings. Front Med (Lausanne)2022; 8: 5–10.
73.
BennettAKeravalaAMakalV, et al.Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2. J Struct Biol2020; 209: 1–2.
74.
PerocheauDPCunninghamSLeeJ, et al.Age-Related seroprevalence of antibodies against AAV-LK03 in a UK population cohort. Hum Gene Ther2019; 30: 79–87.
75.
ElmoreZCOhDKSimonKE, et al.Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. JCI Insight2020; 5: 1–6.
76.
LambTDCollinSPPughEN. Evolution of the vertebrate eye: opsins, photoreceptors, retina and eye cup. Nat Rev Neurosci2007; 8: 960–976.
77.
StraussO. The retinal pigment epithelium in visual function. Physiol Rev2005; 85: 845–881.
78.
GreenbergKPPhamAWerblinFS. Differential targeting of optical neuromodulators to ganglion cell soma and dendrites allows dynamic control of center-surround antagonism. Neuron2011; 69: 713–720.
79.
GaubBMBerryMHHoltAE, et al.Restoration of visual function by expression of a light-gated mammalian ion channel in retinal ganglion cells or ON-bipolar cells. Proc Natl Acad Sci USA2014; 111: 1–7.
80.
BusskampVDuebelJBalyaD, et al.Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science2010; 329: 413–417.
81.
KhabouHOrendorffETrapaniF, et al.Optogenetic targeting of AII amacrine cells restores retinal computations performed by the inner retina. Mol Ther Methods Clin Dev2023; 31: 101107.
82.
Garita-HernandezMChaffiolAGuibbalL, et al.Control of microbial opsin expression in stem cell derived cones for improved outcomes in cell therapy. Front Cell Neurosci2021; 15: 7–10.
83.
GauvainGAkolkarHChaffiolA, et al.Optogenetic therapy: high spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates. Commun Biol2021; 4: 1–7.
Study Details | Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT03326336?rank=1 (accessed 6 October 2024).
86.
WrightWGajjeramanSBatabyalS, et al. Restoring vision in mice with retinal degeneration using multicharacteristic opsin. Neurophotonics2017; 4: 1.
Study Details | A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT05921162 (accessed 6 October 2024).
Study Details | Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT05417126 (accessed 6 October 2024).
91.
Study Details | Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT06048185 (accessed 6 October 2024).
92.
Study Details | Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT04945772 (accessed 6 October 2024).
93.
Study Details | Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT06162585 (accessed 6 October 2024).
Study Details | Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT06292650 (accessed 6 October 2024).
101.
SakaiDTomitaHMaedaA. Optogenetic therapy for visual restoration. Int J Mol Sci2022; 23: 15041.
102.
MontazeriLEl ZarifNTrenholmS, et al.Optogenetic stimulation for restoring vision to patients suffering from retinal degenerative diseases: current strategies and future directions. IEEE Trans Biomed Circuits Syst2019; 13: 1792–1807.
KushibikiTIshiharaM. Application of optogenetics in gene therapy. Curr Gene Ther2018; 18: 40–44.
105.
GeeraertsEClaesMDekeysterE, et al.Optogenetic stimulation of the superior colliculus confers retinal neuroprotection in a mouse glaucoma model. J Neurosci2019; 39: 2313–2325.
106.
BansalHPyariGRoyS. Co-expressing fast channelrhodopsin with step-function opsin overcomes spike failure due to photocurrent desensitization in optogenetics: a theoretical study. J Neural Eng2022; 19: 1–16.
107.
KowalTJProssedaPPNingK, et al.Optogenetic modulation of intraocular pressure in a glucocorticoid-induced ocular hypertension mouse model. Transl Vis Sci Technol2021; 10: 3–4.
108.
GengYLiZZhuJ, et al.Advances in optogenetics applications for central nervous system injuries. J Neurotrauma2023; 40: 1297–1316.
109.
Schneider-WarmeF. The power of optogenetics. Herzschrittmachertherapie + Elektrophysiologie2018; 29: 24–29.
110.
IvanovaEBianchimanoPCoronaC, et al.Optogenetic stimulation of cholinergic amacrine cells improves capillary blood flow in diabetic retinopathy. Invest Ophthalmol Vis Sci2020; 61: 11.
111.
KiełbusMCzapińskiJOdrzywolskiA, et al.Optogenetics in cancer drug discovery. Expert Opin Drug Discov2018; 13: 459–472.
112.
MarcREJonesBWWattCB, et al.Neural remodeling in retinal degeneration. Prog Retin Eye Res2003; 22: 607–655.
113.
ChamberlainKRiyadJMWeberT. Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids. Hum Gene Ther Methods2016; 27: 1–12.
114.
De SilvaSRMooreAT. Optogenetic approaches to therapy for inherited retinal degenerations. Journal of Physiology2022; 600: 4623–4632.
115.
HartmanRRKompellaUB. Intravitreal, subretinal, and suprachoroidal injections: evolution of microneedles for drug delivery. J Ocul Pharmacol Ther2018; 34: 141–153.
116.
FordJLKaratzaEModyH, et al.Clinical pharmacology perspective on development of adeno-associated virus vector-based retina gene therapy. Clin Pharmacol Ther2024; 115: 1212.
117.
CampochiaroPAMirTA. The mechanism of cone cell death in Retinitis Pigmentosa. Prog Retin Eye Res2018; 62: 24–37.
118.
PfeifferRLAndersonJRDahalJ, et al.A pathoconnectome of early neurodegeneration: network changes in retinal degeneration. Exp Eye Res2020; 199: 108196.
